Zicronapine

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Zicronapine
Zicronapine.svg
Identifiers
  • 4-[(1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl]-1,2,2-trimethylpiperazine
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC22H27ClN2
Molar mass354.92 g·mol−1
3D model (JSmol)
  • Clc1ccc4c(c1)[C@H](N2CC(N(C)CC2)(C)C)C[C@H]4c3ccccc3
  • InChI=1S/C22H27ClN2/c1-22(2)15-25(12-11-24(22)3)21-14-19(16-7-5-4-6-8-16)18-10-9-17(23)13-20(18)21/h4-10,13,19,21H,11-12,14-15H2,1-3H3/t19-,21+/m0/s1
  • Key:BYPMJBXPNZMNQD-PZJWPPBQSA-N

Zicronapine (/zˈkrɒnəpn/ zye-KRON-ə-peen, previously known as Lu 31-130) is an atypical antipsychotic medication[1] formerly under development by H. Lundbeck A/S. In phase II studies zicronapine showed statistically significant separation from placebo and convincing efficacy and safety data when compared to olanzapine.[2]

Zicronapine exhibits monoaminergic activity and has a multi-receptorial profile. In vitro and in vivo it has shown potent antagonistic effects at dopamine D1, D2 and serotonin 5HT2A receptors.[3]

In 2014 Lundbeck removed zicronapine from its development portfolio in favor of pursuing the more promising antipsychotic Lu AF35700 (a prodrug of Lu AF356152).[4]

References[edit]

  1. ^ Citrome L (November 2013). "A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach". CNS Drugs. 27 (11): 879–911. doi:10.1007/s40263-013-0105-7. PMID 24062193. S2CID 23867019.
  2. ^ "The clinical phase III programme commenced on zicronapine". January 20, 2011. Retrieved 6 February 2014.
  3. ^ "Zicronapine shows significant positive data in clinical phase II in the treatment of patients with schizophrenia - planning for continued clinical work". December 18, 2009. Retrieved 6 February 2014.
  4. ^ "Performance in 2014 positions Lundbeck well for 2015 and beyond" (PDF). February 5, 2015. Retrieved 18 June 2015.